Relapsed or refractory large B‐cell lymphoma after chimeric antigen receptor T‐cell therapy: Current challenges and therapeutic options

Chimeric antigen receptor (CAR) T-cell (CAR-T) therapy can provide durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after failure of chemoimmunotherapy. However, patients who are refractory or relapsing after CAR-T therapy have poor outcomes. Multiple mechanisms of CAR-T therapy failure have been proposed but management of these patients remains a challenge. As CAR-T therapy moves earlier in the treatment of DLBCL, we urgently need trials focused on patients with relapse after CAR-T therapy. Recent advances in novel immunotherapies such as bispecific antibodies, antibody-drug conjugates and next-generation CAR-T therapies may provide avenues for treatment. Here we review the available data on using these drugs after failure of CAR-T therapy and provide a framework for the ideal sequencing of these novel agents.

[1]  M. Subklewe,et al.  Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy , 2022, Blood.

[2]  L. Gordon,et al.  Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL , 2022, Blood advances.

[3]  D. Miklos,et al.  Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma , 2022, Nature Medicine.

[4]  F. Awan,et al.  Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma , 2022, Haematologica.

[5]  R. Houot,et al.  Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Pabst,et al.  Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy , 2022, Cancers.

[7]  M. Stetler-Stevenson,et al.  Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation , 2022, Journal for ImmunoTherapy of Cancer.

[8]  Lei Feng,et al.  A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy , 2022, Blood advances.

[9]  A. Huitema,et al.  Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia , 2021, Blood advances.

[10]  G. Salles,et al.  Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data , 2021, Blood advances.

[11]  M. Pasquini,et al.  Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis , 2021, Blood advances.

[12]  C. Turtle,et al.  Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission. , 2021, Blood.

[13]  E. Wherry,et al.  Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. , 2021, Blood.

[14]  K. Davis,et al.  CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial , 2021, Nature Medicine.

[15]  G. Lenz,et al.  Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. , 2021, Blood advances.

[16]  A. Rosenwald,et al.  Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma , 2021, Haematologica.

[17]  L. Sellner,et al.  Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies , 2021, Oncology reports.

[18]  S. Schuster.  Bispecific antibodies for the treatment of lymphomas: Promises and challenges , 2021, Hematological oncology.

[19]  P. Hari,et al.  PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response , 2021, Haematologica.

[20]  K. Davis,et al.  CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. , 2020, Blood.

[21]  P. Merlet,et al.  Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. , 2020, Blood advances.

[22]  J. Vose,et al.  Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. , 2020, Blood.

[23]  D. Cunningham,et al.  Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data , 2020 .

[24]  M. Bar,et al.  Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies. , 2020, Blood.

[25]  D. Maloney,et al.  Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy , 2019, American journal of hematology.

[26]  O. Oluwole,et al.  Understanding and managing large B cell lymphoma relapses after CAR T cell therapy. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  Zhen-bo Feng,et al.  Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses. , 2018, International journal of clinical and experimental pathology.

[28]  E. Jaffe,et al.  Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma , 2018, Haematologica.

[29]  Michael L. Wang,et al.  Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. , 2017, Blood.

[30]  B. Coiffier,et al.  Diffuse large B-cell lymphoma: R-CHOP failure-what to do? , 2016, Hematology. American Society of Hematology. Education Program.

[31]  O. Elemento,et al.  Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. , 2016, Blood.

[32]  R. Gascoyne,et al.  Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment , 2015, Annals of Hematology.

[33]  T. Kroll,et al.  Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? , 2014, Bone Marrow Transplantation.